Ajanta Pharma Limited
National Stock Exchange of IndiaTotal Valuation
Ajanta Pharma Limited carries a market capitalization of 421.47B, placing it among publicly traded companies globally. Its enterprise value stands at 322.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 421.47B |
| Enterprise Value | 322.16B |
Valuation Ratios
Ajanta Pharma Limited trades at a trailing price-to-earnings ratio of 34.64.
| PE Ratio | 34.64 |
| PS Ratio | 6.70 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Ajanta Pharma Limited trades at an EV/EBITDA multiple of 13.06 and an EV/FCF ratio of 1,643.22. The EV/Sales ratio of 6.70 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.06 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.70 |
| EV / EBITDA | 13.06 |
| EV / EBIT | 13.06 |
| EV / FCF | 1,643.22 |
Financial Position
Ajanta Pharma Limited maintains a current ratio of 5.93, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.14, indicating elevated leverage, while an interest coverage ratio of 97.66 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.93 |
| Quick Ratio | 1.45 |
| Debt / Equity | 2.14 |
| Debt / EBITDA | N/A |
| Interest Coverage | 97.66 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 1,535.72 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Ajanta Pharma Limited has paid 2.68B in income taxes, reflecting an effective tax rate of 22.38.
| Income Tax | 2.68B |
| Effective Tax Rate | 22.38 |
Stock Price Statistics
Ajanta Pharma Limited's stock has gained approximately 26.95217% over the past 52 weeks. The 50-day moving average sits at 3,079.94, while the 200-day moving average is 2,800.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | 26.95217% |
| 50-Day Moving Average | 3,079.94 |
| 200-Day Moving Average | 2,800.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ajanta Pharma Limited generated 48.06B in revenue and converted that into 9.30B in net income, yielding earnings per share of 74.27. EBITDA reached 24.67B, while operating income came in at 24.67B.
| Revenue | 48.06B |
| Gross Profit | 37.27B |
| Operating Income | 24.67B |
| Pretax Income | 11.98B |
| Net Income | 9.30B |
| EBITDA | 24.67B |
| EBIT | 24.67B |
| Earnings Per Share (EPS) | 74.27 |
Margins
Ajanta Pharma Limited operates with a gross margin of 77.55, reflecting its pricing power and cost economics. The operating margin of 51.33 and net profit margin of 19.35 provide insight into operational efficiency.
| Gross Margin | 77.55 |
| Operating Margin | 51.33 |
| Pretax Margin | 24.93 |
| Profit Margin | 19.35 |
| EBITDA Margin | 51.33 |
Stock Splits
Ajanta Pharma Limited's most recent stock split took place on June 22, 2022 with a 2:3 split ratio.
| Last Split Date | 6/22/2022 |
| Split Ratio | 2:3 |
Scores
Ajanta Pharma Limited posts an Altman Z-Score of 44.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 44.27 |